The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Thirty overweight/obese adults, ≥ 45 years, were randomized to 2 MIB-626 tablets of 500 mg of microcrystalline β-NMN or placebo 2x daily for 28 d. Outcomes included safety; NAD and its metabolome; body weight; liver, muscle, intra-abdominal fat; insulin, blood pressure. lipids.. https://t.co/XADWDqJxGm
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.